anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention relates to a medical field, in particular to a &#39;hypochlorous oxidation oral liquid for oral administration&#39;. The invention uses a strong oxidizing property of nascent oxygen generated by chemical reaction of chlorine and water to remove bacteria and viruses in human bodies. With a strong smell and a simulative property, hypochlorous, when taken orally and alone, can stimulate and cause damages to oral cavity, esophagus, gastric mucosa, etc. Therefore, hypochlorous with a concentration in a certain range can not be taken orally. The invention mainly provides a method for taking the hypochlorous. The method comprises the following steps: pouring boiling water into and fully dissolving a certain amount of brown sugar, honey, milk, etc.; when the liquid is cool enough as to not burn the mouth, adding a certain number of chlorine dissection tablets or a certain amount of bleaching powder with complete stirring; and taking orally. The brown sugar, honey, milk can protect the oral cavity, the esophagus and the gastric mucosa against the simulation of the hypochlorous and can reduce the smell of the hypochlorous. The hypochlorous oxidation oral liquid for oral administration of the invention is used to remove bacteria and viruses in the human bodies by the strong oxidizing property of the hypochlorous. With a proper dosage, the hypochlorous oxidation oral liquid for oral administration can realize the prevention and treatment of diseases with side effect caused by chlorine to the human bodies.
PURPOSE:To obtain an aerosol composition alcohol containing a polyhydric alcohol in a large amount more than a definite value as a stock solution and containing a nonsteroidal antiphlogistic external preparation as an active ingredi ent, free from irritation to nasal mucosa due to foamy or gel-like form in spraying and capable of improving blood circulation. CONSTITUTION:The objective aerosol composition contains &gt;=70wt.% polyhydric alcohol as a stock solution and contains preferably about 0.1-5% nonsteroidal antiphlogistic external preparation. As the polyhydric alcohol, e.g. glycerol, propylene glycol, 1,3-butylene glycol or polyethylene glycol is especially preferably used, because it is high in safety to human body and acts also as humectant. 0.1-20% foam stabilizer and/or gelling agent and about 10% auxiliary agent are preferably further added to the stock solution. The nonsteroidal antiphlogistic external preparation includes e.g. bufexamac, ibuprofen, indomethacin or piroxicam. The aerosol composition consists of 80-98% stock solution and 2-20% liquefied gas (propellant) or 95-99.5% stock solution and 0.1-5% compressed gas (propellant).
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an information search apparatus and an information search method that can allows accurate setting of a complicated search condition.  &lt;P&gt;SOLUTION: Keyword areas corresponding to selected keywords are displayed in a search setting area. Each keyword area is resized or moved to, for example, overlap others so as to satisfy a condition of medical images that requires the arrangement of the keyword areas. One or more areas formed on the search setting area are designated as search areas. A search condition corresponding to the designated search areas is generated for search. If the combination of keyword areas overlapped by resizing or moving is contradictory, the overlap is canceled to prevent areas having no matching medical images from being designated as search areas.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PURPOSE:To make possible the quick and exact quantitative determination of interferon-alpha (IFN-alpha) by using the animal&#39;s red cells sensitized with &gt;=2 kinds of monoclonal anti-IFN-alpha antibody which can discriminate the different antigen determinants for the IFN-alpha as a reagent for measuring the reversed passive hemagglutination. CONSTITUTION:The IFN-alpha which is produced in the human leucocyte, Esche richia coli, Bacillus subtilis, etc. in genetic engineering is immunized with the BALC/C mouse and the spleen cells thereof are made confluent with the myeloma cells. The anti-IFN-alpha antibody producing strains are obtd. from such confluent cells. The antibodies obtd. by combining two kinds each among 5 kinds of the resultant producing strains are sensitized with the red cells of goat, fowl, etc. and the anti-IFN-alpha antibody sensitized red cells are obtd. A bovine albumin is added to the sensitized red cells which are then freeze-dried to obtain the reagent. The reagent, the standard INF-alpha positive control and negative control as well as a buffer soln. are combined to make a kit for meas uring the reversed passive hemagglutination. The reagent for the quick and exact measurement of the INF-alpha is thus obtd.
A severed nerve may be surgically rejoined and severed axons fused via sequential administrations of solutions. The solutions may include a priming solution comprising methylene blue in a Ca&lt;sup&gt;2+&lt;/sup&gt;-free saline solution, a fusion solution comprising about 50% (w/w) PEG, and a sealing solution comprising Ca&lt;sup&gt;2+&lt;/sup&gt;-containing saline. The PEG fusion solution may be applied in a nerve treatment device configured to isolate the injured segment of the nerve. The device may include a containment chamber for creating a fluid containment field around the anastomosis. The device may have slits, slots, and/or apertures in opposing endwalls of the device designed to receive the nerve. The device may have an open bath configuration or may include separable lower and upper bodies to create a closed bath configuration. The device may include one or more fluid ports in fluid communication with the containment chamber for introducing and/or removing fluid.
The invention belongs to the field of traditional Chinese medicine pharmacy, and specifically relates to plaster for treating bone fracture and a preparation method of the plaster. The plaster is prepared from the following raw materials, by weight part, coarse traditional Chinese medicine materials, fine traditional Chinese medicine materials, vegetable oil, and minium. The adopted traditional Chinese medicine materials conform to regulations of Pharmacopoeia of the People&#39;s Republic of China and are safe and reliable. The medicines match each other and have the efficacy of activating blood and resolving stasis, dispersing swelling and relieving pain, relaxing sinews and regulating qi, dissipating cold and dispelling wind, and conducting union of fractured tendons and bones. The plaster can treat bone fracture, has a precise and fast curative effect, and is high in cure rate and free of side effect. The plaster is applied to: 1, all kinds of organic lesions about bones and joints, such as various kinds of arthritis, periarthritis humeroscapularis, cervical spondylosis, hyperosteogeny, and bony spurs; 2, all kinds of traumatic skin, bone, tendon and vessel lesions, such as various kinds of wounds, bone fracture, and tendon and vessel clonus; and 3, muscle strain lesions at all parts, such as waist soreness and backache, and cervicobrachial (muscle) pain.
&lt;P&gt;PROBLEM TO BE SOLVED: To improve the productivity in indigo dyeing by shortening a preparation time and omitting steps in a process of preparing a dyeing liquor for indigo dyeing.  &lt;P&gt;SOLUTION: A new indigo reductase is produced by an enzyme, especially Bacillus cohnii reducing indigo into leuco indigo. A Bacillus cohnii BC-001 strain äNITE (National Institute of Technology and Evaluation), accession number (NITE) P-15} which is a microorganism producing the indigo reductase is provided. A method for producing the indigo reductase comprises preparing the indigo reductase from a cultured product of the microorganism. Thereby, uses of the indigo reductase are provided.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a composition for ameliorating a blood viscosity, keeping the blood in a smooth state with a low viscosity, useful for maintenance and recovery of health, and derived from buckwheat.  &lt;P&gt;SOLUTION: This composition for ameliorating the blood viscosity contains a solvent extract of an above-ground part including one kind or more of a leaf part, a stem part and a flower part of the buckwheat. The extraction solvent of the solvent extract is preferably hydrated ethanol. A deep water may also be used as the extraction solvent of the solvent extract. The composition for ameliorating the blood viscosity is preferably used by being formulated with a food and drink, or a medicine.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a composition for the oral cavity, which prevents and ameliorates periodontal disease.  &lt;P&gt;SOLUTION: The composition for the oral cavity is obtained by mixing an extract derived from a crude medicine, having hemostatic and/or antiphlogistic and anti-inflammatory effect with a propolis extract. The crude medicine is a plant belonging to the genus Daucus of the family Araliaceae. The plant is Denshichi Ginseng. The amount of the crude medicine mixed is 0.01-15.0 wt.%. The amount of the propolis extract mixed is 0.01-10.0 wt.%. A plant body itself, leaves, stems, rhizomes, roots, etc., may be cited as a part to be used for obtaining the material derived from the crude medicine. One or more of them are used alone or together. Among them, the roots are preferable due to containing a large amount of a triterpene-based saponin.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
Articles of clothing, such as stocking, socks, knee-leggings, mittens, gloves, underwear, caps, or materials employed in making such articles, or surgical dressings, such as lining material or cottonwool, are rendered radio-active for therapeutic purposes by impregnating them, as by spraying, with a solution of radium chloride, and subsequently treating the impregnated material with an insolubilizing agent such as Glauber&#39;s salt solution.  The products may be treated with protective agents such as wax, or oil emulsions. The Specification as open to inspection under Sect. 91 describes also the application of the radio-active material in finely divided form and the use of a solution of any radio-active salt subsequently insolubilized.  This subject-matter does not appear in the Specification as accepted.ALSO:Articles of clothing, such as stockings, socks, knee-leggings, mittens, gloves, underwear, caps, or materials employed in making such articles, or surgical dressings, such as lining material or cottonwool, are rendered radioactive for therapeutic purposes by impregnating them, as by spraying, with a solution of radium chloride, and subsequently treating the impregnated material with an insolubilizing agent such as Glauber&#39;s salt solution.  The products may be treated with protective agents such as wax, or oil emulsions.  The Specification as open to inspection under Sect. 91 also describes the application of the radioactive material in finely divided form and the use of a solution of any radioactive salt subsequently insolubilized.  This subject-matter does not appear in the Specification as accepted.ALSO:Articles of clothing, such as stockings, socks, knee-leggings, mittens, gloves, underwear, caps, or materials employed in making such articles, or surgical dressings, such as lining material or cottonwool, are rendered radio-active for therapeutic purposes by impregnating them, as by spraying, with a solution of radium chloride, and subsequently treating the impregnated material with an insolubilizing agent such as Glauber&#39;s salt solution.  The products may be treated with protective agents such as wax, or oil emulsions.  The Specification as open to inspection under Sect. 91 also describes the application of the radio-active material in finely-divided form and the use of a solution of any radio-active salt subsequently insolubilized.  This subject-matter does not appear in the Specification as accepted.
FIELD: medicine, organic chemistry, biochemistry, peptides. SUBSTANCE: invention relates to synthesis of peptides. Invention claims the novel heptapeptide: lysyl-glutamyl-aspartyl-alanyl-prolyl-glycyl-proline of the general formula: Lys-Glu-Asp-Ala-Pro-Gly-Pro eliciting stimulating and regulating effect on protein synthesis in hepatocytes. Proposed heptapeptide shows ability to effect biochemical parameters in function of endogenous opioid system. Heptapeptide doesn&#39;t elicit psychotropic effect and doesn&#39;t affect psychomotor activity of animals in used behavioral tests. Proposed heptapeptide can be used as a base for development of medicinal forms eliciting hepatoprotective activity. EFFECT: valuable medicinal and biochemical properties of peptide. 1 dwg, 4 tbl, 3 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a blood purifying body capable of purifying blood by contact with the skin of the human body.  &lt;P&gt;SOLUTION: The blood purifying body is composed of: the first material selected from a group consisting of a copper material, a platinum material and molybdenum material; the second material selected from a group consisting of a black silica material, a radon material, a germanium material, an Nd material and a silica material; and a titanium oxide material. At least the titanium oxide material is disposed in the contact part in contact with the skin of the user. The contact part is composed of a blended coating layer 12 containing the second material and the titanium oxide material, or composed of a surface coating layer 23 including the titanium oxide material. An intermediate coating layer 22 including the second material and a cover base 21 are disposed in this order under the surface coating layer 23.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain the subject composition suppressing adsorption and penetration of a perfume and continuing a refreshing feeling by blending a large amount of ethanol with citral and menthol in a specific ratio and packing the blend into a container made of a specific synthetic resin. SOLUTION: This composition is obtained by blending &gt;=20% of ethanol with citral and menthol in the weight ratio of 2:1 to 1:50 (especially 1:1 to 1:10) and is packed into a container made of a synthetic resin having the ratio (cm&lt;2&gt; /ml) of the inner area of the container in contact with the composition to the composition volume of &gt;=2, especially 4-5. A container made of a polyethylene terephthalate is preferable as the container. The amount of menthol blended is preferably 0.01-2.0wt.% and that of citral is preferably 0.001-1.0%. The composition to be packed is preferably a liquid or in a liquid state. The composition is preferably mixed with a polyoxyethylene hardened castor oil having 40-100 addition mols of ethylene oxide.
Use of a cationic hydrotrope i.e. phenyl or pyridinium derivative (I) in a coloring process of keratinous fibers. The electroneutrality of the compound is assured by an anion or a mixture of anions. Use of a cationic hydrotrope i.e. phenyl or pyridinium derivative of formula (I) in a coloring process of keratinous fibers. The electroneutrality of the compound is assured by an anion or a mixture of anions. X : CH or N +&gt;R 6; R 61-10C, preferably 1-6C alkyl; R 1H, 1-10C, preferably 1-6C alkyl (when X is N +&gt;R 6) or -(CH 2) nN +&gt;R 3R 4R 5 (when X is CH); R 3-R 51-10C alkyl; n : 0-12; R 21-4C alkyl; and p : 0-1. Independent claims are included for: (1) a tinctorial composition for the coloring of human keratinous fibers, comprising (I) and a direct dye and/or an oxidation dye, in a medium; and (2) a process coloring of keratinous fibers, comprising applying the tinctorial composition optionally in combination with a simultaneous of successive application of an oxidizing composition comprising an oxidant on the keratinous fibers, leaving for some time to obtain a desired effect, optionally rinsing the fibers and shampooing and rinsing the fibers, followed by drying or leaving to dry. [Image].
&#34;Black holes&#34; in the genomes of bacterial pathogens represent deletions of &#34;anti-virulence&#34; genes, i.e. genes that are detrimental to a pathogenic lifestyle. Identification of the missing genetic loci in the &#34;black hole&#34; identifies genes that are incompatible with the bacteria&#39;s pathogenicity. These genes, their gene products, and compounds generated by the enzymatic action of these gene products represent potential new compounds that are inhibitory to the bacterial pathogen and thus useful as pharmaceuticals. The utility of this concept is demonstrated in the missing gene for lysine decarboxylase, and the resulting inhibitory activity of cadaverine (the diaminoalkyl reaction product of lysine decarboxylase) on the Shigella enterotoxins. Diaminoalkyl compounds are therefore potent inhibitors of E. coli and Shigella spp. enterotoxins. Lysine decarboxylase generated from the gene cadA results in attenuation of the enterotoxic effects. New methods of use of diaminoalkyl compounds as medicaments are described. New uses of genetic constructs containing a cadA sequence, or other &#34;anti-virulence&#34; gene, for biochemical probes, for toxin receptor identification, and for pharmaceutical discovery are described. Additional uses are described for vaccines and DNA vaccine delivery.
The invention comprises compounds of the formula &lt;FORM:1016372/C2/1&gt; wherein the dotted line in ring A denotes the optional presence of double bonds, R1 represents a hydrogen atom or a methyl group, R2 represents two hydrogen atoms when a D 4 double bond is absent, or a hydrogen or chlorine atom or a hydroxyl group when a D 4 double bond is present, R3 represents a hydrogen atom or an alkyl group preferably having less than six carbon atoms, R4 represents two hydrogen atoms or one hydrogen atom with an a -methyl group, and X represents a chlorine atom or the group -OR in which R represents an alkyl, alkenyl, cycloalkyl, aryl, halo-substituted aryl, aralkyl, alkaryl, alkoxyaryl, aryloxy alkyl or heterocyclic radical.  The compounds may be prepared by direct acylation of a steroid compound having a hydroxy group in the 17b  position with chlorosulphonylacetyl chloride in an inert solvent to give the sulphonyl chloride. The sulphonate esters may be prepared by reaction of the sulphonyl chloride so produced with an alcohol or directly by addition of an alcohol during the acylation.  The sulphoacetates may be prepared from 3,17-androstenediones by protecting the D 4-3-keto position, reducing the 17-keto group and reacting with chlorosulphonyl acetyl chloride.  Esters of testosterone-17-sulphoacetate may be prepared by treating testosterone with a Grignard reagent and reacting the resulting 17-halomagnesium compound with chlorosulphonylacetyl chloride and an alcohol.  Therapeutic compositions with anabolic and androgenic properties, in the form of oil solutions or aqueous suspensions for parenteral administration, contain esters of androstaneand estrane-17-sulphoacetates of the above general formula.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a device for maintaining and reinforcing a proper intervertebral disc space when an intervertebral prosthesis is introduced into a cavity in the intervertebral disc space.  &lt;P&gt;SOLUTION: A device and method are provided for maintaining a proper intervertebral disc height during the replacement or augmentation of the spinal disc. In one embodiment, a cannulated distractor 10 is used to distract the adjacent vertebrae and maintain a proper disc space height. The cannulated distractor 10 is fluidly connected to a source of fluent material for injection into the disc space. The distraction member includes a distraction tip 18 resident within the intervertebral disc space that includes a central lumen and a number of openings 30, 32 communicating with the lumen to dispense the fluent material within the disc space.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To prepare a cosmetic, useful for beautifying and face beautification and free from toxicity against the skin by compounding an essence obtained by extracting a specific material to be used as a raw material of a Chinese medicine or a food material of a Chinese dish with water as an active component. SOLUTION: ENKA(a kind of an edible bird&#39;s nest) is finely cut, and the resultant pieces of ENKA is extracted with water at a temperature ranging from the ambient temperature to about 120 deg.C. Water is removed from the extract to obtain ENKA extract, which is used as an active component. The ENKA extract is crystalline powder or powder of white to yellowish white to blown, and contains saccharides, proteins and further acyl acids. The cosmetic is excellent in safety and can be easily compounded in a cream, a milky lotion, a lip stick, an eye shadow, a shampoo, a hair rinse, etc. A compounding ratio of the ENKA extract is preferably about 0.05-10wt.%.
1,211,171. Thieno-benzothiazepines. J. R. GEIGY A.G. 29 Nov., 1968 [30 Nov., 1967; 29 Dec., 1967], No. 56702/68. Heading C2C. Novel thieno-benzothiazepines of Formula (I) in which n is 2 or 3, R is hydrogen or methyl, X is hydrogen or chlorine and Z is hydrogen, C 1-4 alkyl, C 1-4 hydroxyalkyl, C 3-9 alkanoyloxyalkyl or cyclopropyl, and their acid addition salts, are prepared by reacting a compound of Formula (II) in which Q is halogen or C 1-4 alkoxy, with a compound of Formula (III) in which Z has the same meaning as Z or it represents a radical which can be replaced by hydrogen by hydrolysis, or an alkali metal derivative thereof, if necessary hydrolysing the product obtained to convert the radical Z&lt;SP&gt;1&lt;/SP&gt;. into hydrogen, optionally converting a product obtained, in which Z is hydrogen, into a product in which Z is a C 1-4 alkyl, C 1-4 hydroxyalkyl or C 3-9 alkanoyloxyalkyl group, or acylating a product in which Z is C 1-4 hydroxyalkyl, into one in which Z is C 3-9 alkanoyloxyalkyl, or hydrolysing a product obtained in which Z is C 3-9 alkanoyloxyalkyl into one in which Z is C 1-4 hydroxyalkyl, and if desired, converting a compound of Formula (I) obtained into an acid addition salt. Starting materials of Formula (II), in which Q is chlorine, are prepared by reacting a compound of Formula (IV) with phosphorus pentachloride. The compound of Formula (II), in which X is hydrogen and Q is ethoxy, is prepared by reacting the corresponding compound, in which Q is chlorine, with ethanol. Thieno - benzothiorepinones of Formula (IV) are prepared by reacting 2-amino-thiophenol or 2-amino-4-chloro-thiophenol with 3-bromothiophene to give a (3-thienylthio)-aniline, reacting this with phosgene to give a (3-thienylthio)-phenyl isocyanate and cyclizing this using aluminium chloride. Pharmaceutical compositions having a central depressant action, for oral, rectal or parenteral administration, comprise a compound of Formula (I), or a pharmaceutically acceptable acid addition salt thereof, together with a carrier.
[GB1211171A]